Department of Medicine and Research Center, Montreal Heart Institute, Montreal, Quebec, Canada.
Circ Res. 2011 Oct 14;109(9):1031-43. doi: 10.1161/CIRCRESAHA.111.253120. Epub 2011 Sep 8.
Atrial fibrillation (AF) causes atrial-tachycardia remodeling (ATR), with enhanced constitutive acetylcholine-regulated K+ current (I(KAChC)) contributing to action potential duration shortening and AF promotion. The underlying mechanisms are unknown.
To evaluate the role of protein-kinase C (PKC) isoforms in ATR-induced I(KAChC) activation.
Cells from ATR-dogs (400-bpm atrial pacing for 1 week) were compared to control dog cells. In vitro tachypaced (TP; 3 Hz) canine atrial cardiomyocytes were compared to parallel 1-Hz paced cells. I(KAChC) single-channel activity was assessed in cell-attached and cell-free (inside-out) patches. Protein expression was assessed by immunoblot. In vitro TP activated I(KAChC), mimicking effects of in vivo ATR. Discrepant effects of PKC activation and inhibition between control and ATR cells suggested isoform-selective effects and altered PKC isoform distribution. Conventional PKC isoforms (cPKC; including PKCα) inhibited, whereas novel isoforms (including PKCε) enhanced, acetylcholine-regulated K+ current (I(KACh)) in inside-out patches. TP and ATR downregulated PKCα (by 33% and 37%, respectively) and caused membrane translocation of PKCε, switching PKC predominance to the stimulatory novel isoform. TP increased [Ca2+]i at 2 hours by 30%, with return to baseline at 24 hours. Buffering [Ca2+]i during TP with the cell-permeable Ca2+ chelator BAPTA-AM (1 μmol/L) or inhibiting the Ca2+-dependent protease calpain with PD150606 (20 μmol/L) prevented PKCα downregulation and TP enhancement of I(KAChC). PKCε inhibition with a cell-permeable peptide inhibitor suppressed TP/ATR-induced I(KAChC) activation, whereas cPKC inhibition enhanced I(KAChC) activity in 1-Hz cells.
PKC isoforms differentially modulate I(KACh), with conventional Ca(2+)-dependent isoforms inhibiting and novel isoforms enhancing activity. ATR causes a rate-dependent PKC isoform switch, with Ca2+/calpain-dependent downregulation of inhibitory PKCα and membrane translocation of stimulatory PKCε, enhancing I(KAChC). These findings provide novel insights into mechanisms underlying I(KAChC) dysregulation in AF.
心房颤动(AF)导致心房性心动过速重构(ATR),增强的乙酰胆碱调节的钾电流(I(KAChC))有助于动作电位持续时间缩短和 AF 促进。其潜在机制尚不清楚。
评估蛋白激酶 C(PKC)同工型在 ATR 诱导的 I(KAChC)激活中的作用。
将 ATR-犬(400bpm 心房起搏 1 周)的细胞与对照犬细胞进行比较。将体外快速起搏(TP;3Hz)犬心房肌细胞与平行的 1Hz 起搏细胞进行比较。在细胞附着和无细胞(内向外)贴片中评估 I(KAChC)单通道活性。通过免疫印迹评估蛋白表达。体外 TP 激活了 I(KAChC),模拟了体内 ATR 的作用。对照和 ATR 细胞之间 PKC 激活和抑制的不一致效应表明同工型选择性效应和改变的 PKC 同工型分布。传统 PKC 同工型(cPKC;包括 PKCα)抑制,而新型同工型(包括 PKCε)增强乙酰胆碱调节的钾电流(I(KACh))在无细胞贴片中。TP 和 ATR 下调 PKCα(分别下调 33%和 37%)并引起 PKCε的膜易位,将 PKC 优势切换为刺激新型同工型。TP 在 2 小时时将 [Ca2+]i 增加 30%,24 小时时恢复基线。用细胞通透性 Ca2+螯合剂 BAPTA-AM(1μmol/L)缓冲 TP 期间的 [Ca2+]i 或用钙依赖性蛋白酶 calpain 的抑制剂 PD150606(20μmol/L)抑制,可防止 PKCα 下调和 TP 增强 I(KAChC)。用细胞通透性肽抑制剂抑制 PKCε可抑制 TP/ATR 诱导的 I(KAChC)激活,而 cPKC 抑制增强 1Hz 细胞中的 I(KAChC)活性。
PKC 同工型差异调节 I(KACh),传统的 Ca2+依赖性同工型抑制,新型同工型增强活性。ATR 导致依赖于速率的 PKC 同工型转换,Ca2+/钙蛋白酶依赖性下调抑制性 PKCα 和刺激性 PKCε 的膜易位,增强 I(KAChC)。这些发现为 AF 中 I(KAChC)失调的潜在机制提供了新的见解。